Inhibitors of glucose-6-phosphate translocase (G6P T1) control aberrant glucose levels and show promise as anticancer and anti-diabetic agents. This mini-review provides a concise overview of natural product and natural product analogs that inhibit G6P T1. The discovery and development of these inhibitors, as well as their efficacy in cell-based assays and in vivo, are discussed. Finally, we acknowledge the need for improved G6P T1 inhibitors and the potential to harness the programmable chemistry of microorganisms to meet this need.
No takes yet. Share an insight, caveat, or question.
Charkoudian et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: